Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 10:30 a.m. PT / 1:30 p.m. ET.
Investors can access presentation materials and slides on the company's investor relations events page at the time of posting.
Details
News Market Reaction – DNA
On Jan 13, the day this news came out, DNA closed 0.63% above the previous close.
Data tracked by StockTitan Argus for the Jan 13 session.
Key Figures
- Conference date
- January 15, 2026
- J.P. Morgan Healthcare Conference presentation date
- Presentation time (PT)
- 10:30 a.m. PT
- Scheduled conference presentation time
- Presentation time (ET)
- 1:30 p.m. ET
- Scheduled conference presentation time
Historical Context
-
ARPA-H backed POSEIDON oncology screening partnership with Carnegie Mellon.
-
Collaboration with Agricen to optimize fermentation for soil amendment product.
-
ARPA-H funded PREDICTS drug safety data platform with Deep Origin.
-
Four-year, up to $47M contract for high-throughput phenotyping platform.
-
Participation in STRM.BIO’s ARPA-H EMBODY-funded MV gene therapy program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Further details, including slides, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. Ginkgo R&D Solutions delivers customizable R&D packages—such as protein engineering, nucleic acid design, and cell-free systems—giving partners a comprehensive way to accelerate innovation across therapeutics, diagnostics, & manufacturing. Ginkgo Automation sells modular, integrated laboratory automation so scientists can spend their days planning and analyzing experiments rather than pipetting in the lab. Ginkgo Datapoints uses Ginkgo's in-house automation to generate the large lab data sets to power your AI models. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
investors@ginkgobioworks.com
MEDIA CONTACT:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-the-44th-annual-jp-morgan-healthcare-conference-302659475.html
SOURCE Ginkgo Bioworks
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.